Negative in Ames, in vitro chromosomal aberration and rat bone marrow micronucleus assays
“Belumosudil was not mutagenic in the in vitro bacterial reverse mutation test or clastogenic in either the in vitro chromosomal aberrations assay in human peripheral lymphocytes or in the vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Carcinogenicity
6-month Tg(HRAS) transgenic mouse: no carcinogenic effect up to 15 (F) and 30 (M) mg/kg/day
“Belumosudil did not result in any carcinogenic effect in a 6-month CByB6F1-Tg (HRAS)2Jic hemizygous mouse study at oral doses up to 15 mg/kg/day in female and 30 mg/kg/day in male mice.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rabbit EFD: abortion, fetal loss, reduced fetal weight and skeletal/external malformations from 50 mg/kg/day
“Embryo-fetal findings occurred at doses ≥ 50 mg/kg/day and included spontaneous abortion, increased post-implantation loss, decreased percentage of live fetuses, decreased fetal body weight, and skeletal/external malformations.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Safety pharmacology
hERG IC50 0.6 µM
“Belumosudil blocked hERG (human ether-à-go-go-related gene) current in a concentration-dependent manner with an IC50 of 0.6 µM.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Genotox: Ames
Negative
“Belumosudil was not mutagenic in the in vitro bacterial reverse mutation test or clastogenic in either the in vitro chromosomal aberrations assay in human peripheral lymphocytes or in the vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Genotox: in vitro mammalian
Chromosomal aberration in human peripheral lymphocytes: negative
“Belumosudil was not mutagenic in the in vitro bacterial reverse mutation test or clastogenic in either the in vitro chromosomal aberrations assay in human peripheral lymphocytes or in the vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative
“Belumosudil was not mutagenic in the in vitro bacterial reverse mutation test or clastogenic in either the in vitro chromosomal aberrations assay in human peripheral lymphocytes or in the vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Carcinogenicity model
6-month CByB6F1-Tg(HRAS)2Jic mouse: no carcinogenic effect up to 15 (F) / 30 (M) mg/kg/day
“Belumosudil did not result in any carcinogenic effect in a 6-month CByB6F1-Tg (HRAS)2Jic hemizygous mouse study at oral doses up to 15 mg/kg/day in female and 30 mg/kg/day in male mice.”
None at US marketing application; mouse and rat carcinogenicity studies required after approval (PMRs)
“PMR #9 Conduct a rodent carcinogenicity study in mice to evaluate the potential for carcinogenicity.”
✓ VerifiedFDA multi-discipline review, p. 280Source ↗
hERG / QT
hERG IC50 well above unbound clinical Cmax (0.0055 µM)
“Considering unbound fraction (fu) of only 0.12% for belumosudil in human plasma (Study KDM/06), Cmax in human plasma corresponds to 2.5 ng/mL (0.0055 µM) unbound compound, which is significantly below IC50 for hERG inhibition.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative